Raj Natarajan, host of ShareTreck, goes behind the scenes with Jeff Galvin, Founder and CEO of American Gene Technologies® to discover how groundbreaking gene therapy technology could be on the verge of disrupting big pharma to become the next trillion dollar industry. Jeff explains how gene therapy works, and what it means for people with deadly diseases, as well as… [Read More]
Economies of scale can apply to gene therapy too Gene therapy’s advantage is its ability to modify the genetic cause of disease. The approach has the potential to correct genetic errors, cure genetic disease and fight serious infections using the body’s own machinery. Its capabilities seem almost limitless, as does the cost of recently approved therapies. However, gene therapy’s mechanistic… [Read More]
Contributing Author John Vandermosten, Senior Biotechnology Analyst Transaction Trends 2021: Pandora’s Box 2020 was a tremendous year for Initial Public Offerings (IPOs) where 494 new issues came to market, but the achievement was eclipsed in 2021 with an all-time record of 1,058 companies going public. In healthcare/life sciences, we counted 118 IPOs in 2020, rising to an impressive 147 in 2021. … [Read More]
Contributing Author John Vandermosten, Senior Biotechnology Analyst Cell therapy is the transfer of therapeutic cells to a patient. It replaces damaged cells or enhances normal cells with modified new ones. The cells used in the process may be autologous or allogeneic; however, they must be recognized by the immune system in a way that will promote the desired response. Some cell… [Read More]
Despite the impact of the pandemic and the seemingly solitary focus of the health care machine on addressing SARS-CoV-2, the gene therapy space continued to progress over the last 18 months. Several new approvals were granted and promising candidates were advanced in clinical trials and submitted to regulatory authorities. CAR T has dominated recent gene therapy approvals with three receiving… [Read More]
Contributing Author: Gina Hagler Big Picture Gene therapy, stem cell therapy, CAR-T, cell therapy and gene editing are all forms of genomic medicine1 – an approach to cure and treat human diseases that uses human biology rather than chemical compounds made in the lab. All of these tools are unlocking techniques and therapies with the power to cure… [Read More]
What Is A SPAC Anyway? 2020 turned out to be a fantastic year for private companies to go public. In a hot year for initial public offerings (IPOs), one type of IPO called a Special Purpose Acquisition Company or SPAC has stolen the spotlight. While they have raised billions, SPACs have no revenues, no operations and no products. But… [Read More]
Contributing Author: Gina Hagler Pharmaceutical companies have been developing therapies to treat or prevent disease since the end of the 19th century. Chemical compounds are used to create these drugs and medications. The resulting small-molecule drugs – think aspirin – are ingested, metabolized and circulate through the blood. Because it’s not possible to target these drugs, they have a systemic… [Read More]
Contributing Author: Gina Hagler Maryland is home to one of the largest life science clusters in the United States with more than 500 biotech companies. In addition to several state-of-the-art labs, Maryland is home to the NIH in Bethesda. Research opportunities, as well as BS and MS degree programs, are offered at Johns Hopkins in Baltimore and the University of Maryland… [Read More]
Written by Jeff Galvin, CEO of American Gene Technologies® The birth of high-value therapeutics and cures Does the development of effective drugs have to be incredibly expensive? Maybe not anymore. There is a new type of drug development emerging: Gene Therapy. The hallmark of gene therapy is the ability to edit or modify the drivers of disease at the most fundamental… [Read More]
Contributing Author John Vandermosten, Senior Biotechnology Analyst Examining events of the past can give us a sense of what to expect in the periods ahead. And despite the omnipresent warning that “past performance is not indicative of future results” we will share some historical trends on biotech performance surrounding economic contractions that may prove useful in the current environment. The pandemic… [Read More]
Jeff Galvin, CEO of American Gene Technologies® provided testimony in a Senate Hearing on March 8, 2016 in support of Maryland’s Biotechnology Investment Incentive Tax Credit. His goal? To alter the definition of “qualified Maryland biotechnology company” so that an active business may claim the biotechnology tax credit – empowering gene therapy startups in the state of Maryland.
Subscribe to our newsletter to keep up to date with all the latest news about AGT!